MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Organon & Co

Închisă

SectorSănătate

14.41 -2.17

Rezumat

Modificarea prețului

24h

Curent

Minim

14.07

Maxim

14.69

Indicatori cheie

By Trading Economics

Venit

-250M

109M

Vânzări

10M

1.6B

P/E

Medie Sector

4.357

63.778

EPS

0.9

Randament dividend

7.72

Marjă de profit

6.847

Angajați

10,000

EBITDA

-64M

338M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+30.43% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

7.72%

2.39%

Următoarele câștiguri

1 mai 2025

Data viitoare de dividende

12 iun. 2025

Următoarea dată ex-dividende

9 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-304M

3.7B

Deschiderea anterioară

16.58

Închiderea anterioară

14.41

Sentimentul știrilor

By Acuity

15%

85%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Organon & Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 apr. 2025, 23:04 UTC

Top știri

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr. 2025, 22:40 UTC

Principalele dinamici ale pieței

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr. 2025, 18:51 UTC

Achiziții, Fuziuni, Preluări

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr. 2025, 22:22 UTC

Achiziții, Fuziuni, Preluări

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr. 2025, 22:21 UTC

Achiziții, Fuziuni, Preluări

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr. 2025, 21:43 UTC

Top știri
Câștiguri

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr. 2025, 20:34 UTC

Top știri

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr. 2025, 20:23 UTC

Top știri

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr. 2025, 20:15 UTC

Achiziții, Fuziuni, Preluări

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr. 2025, 18:38 UTC

Top știri

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr. 2025, 18:30 UTC

Top știri

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparație

Modificare preț

Organon & Co Așteptări

Obiectiv de preț

By TipRanks

30.43% sus

Prognoză pe 12 luni

Medie 19.2 USD  30.43%

Maxim 24 USD

Minim 16 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOrganon & Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

6 ratings

1

Cumpărare

3

Păstrare

2

Vânzare

Scor tehnic

By Trading Central

14.1 / 14.89Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.